Literature DB >> 10619277

Comparison of different systems to classify the neurological level of lesion in patients with myelomeningocele.

A Bartonek1, H Saraste, L M Knutson.   

Abstract

In 73 patients with myelomeningocele (mean 17.2 years, range 5 to 40 years) the classification of level of lesion was studied according to six commonly used classification systems and to the ambulation groups of Hoffer. The distribution of the patients into classes of thoracic-level lesions was the same for four classification systems in 10 patients and for two classification systems into categories of level L3 in 14 patients. For the other patients discrepancies occurred between systems for lesions of level L3 and downward. None of the patients was consistently categorized in the functional ambulation groups of Hoffer using all classification systems. The results show that it is not possible to compare neurological lesion levels classified according to the different systems described in this study and consequently that the distribution into the functional ambulation groups of Hoffer varies. To enhance communication and facilitate comparing the results of treatment we suggest using some basic criteria for patient documentation.

Entities:  

Mesh:

Year:  1999        PMID: 10619277     DOI: 10.1017/s0012162299001607

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  11 in total

1.  Correlation Between Neurologic Impairment Grade and Ambulation Status in the Adult Spina Bifida Population.

Authors:  Anne C Tita; John R Frampton; Christian Roehmer; Sara E Izzo; Amy J Houtrow; Brad E Dicianno
Journal:  Am J Phys Med Rehabil       Date:  2019-12       Impact factor: 2.159

Review 2.  Who needs surgery for pediatric myelomeningocele? A retrospective study and literature review.

Authors:  Humberto Marreiros; Clara Loff; Eulália Calado
Journal:  J Spinal Cord Med       Date:  2014-07-16       Impact factor: 1.985

3.  Factors Associated with Mobility Outcomes in a National Spina Bifida Patient Registry.

Authors:  Brad E Dicianno; Amol Karmarkar; Amy Houtrow; Theresa M Crytzer; Katelyn M Cushanick; Andrew McCoy; Pamela Wilson; James Chinarian; Jacob Neufeld; Kathryn Smith; Diane M Collins
Journal:  Am J Phys Med Rehabil       Date:  2015-12       Impact factor: 2.159

4.  Establishing Content Validity Evidence of the Pittsburgh Impairment Testing Tool (PITT) for Adults With Spina Bifida.

Authors:  Alan Cuevas Villagomez; Gina McKernan; Amy J Houtrow; Brad E Dicianno
Journal:  Top Spinal Cord Inj Rehabil       Date:  2022-08-17

Review 5.  Surgical Management of Hip Problems in Myelomeningocele: A Review Article.

Authors:  Taghi Baghdadi; Reza Abdi; Ramin Zargar Bashi; Hossein Aslani
Journal:  Arch Bone Jt Surg       Date:  2016-06

6.  Associations between orthopaedic findings, ambulation and health-related quality of life in children with myelomeningocele.

Authors:  Aina J Danielsson; Asa Bartonek; Eric Levey; Kathleen McHale; Paul Sponseller; Helena Saraste
Journal:  J Child Orthop       Date:  2007-12-15       Impact factor: 1.548

7.  Pain and health status in adults with myelomeningocele living in Sweden.

Authors:  Ann Alriksson-Schmidt; Annika Lundkvist Josenby; Barbro Lindquist; Lena Westbom
Journal:  J Pediatr Rehabil Med       Date:  2018

8.  Adults with spina bifida: A cross-sectional study of health issues and living conditions.

Authors:  Martina Bendt; Hanna Gabrielsson; Dorothee Riedel; Göran Hagman; Claes Hultling; Erika Franzén; Mats Eriksson; Åke Seiger
Journal:  Brain Behav       Date:  2020-07-07       Impact factor: 2.708

9.  Myelomeningocele: a new functional classification.

Authors:  Luciano S Dias; Vineeta T Swaroop; Luiz R A de Angeli; Jill E Larson; Ana-Marie Rojas; Tasos Karakostas
Journal:  J Child Orthop       Date:  2021-02-01       Impact factor: 1.548

10.  Assessment on self-care, mobility and social function of children with spina bifida in Turkey.

Authors:  Hulya Sirzai; Beril Dogu; Selamet Demir; Figen Yilmaz; Banu Kuran
Journal:  Neural Regen Res       Date:  2014-06-15       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.